IDSA and HIVMA are pleased that global efforts to end the HIV, tuberculosis and malaria epidemics received much needed investment at the seventh replenishment of the Global Fund to Fight AIDS, Tuberculosis and Malaria.
IDSA and HIVMA strongly oppose government interference in the patient-health care provider relationship and religious refusal laws and regulations that allow health care professionals, employers, systems or insurers to deny access to services based on their own personal religious beliefs.
HIVMA is deeply disturbed by today’s ruling by a U.S. District Court judge that allows employers in Texas to deny health care coverage for HIV pre-exposure prophylaxis — a highly effective biomedical intervention for preventing HIV infection.
HIVMA welcomes the release of the comprehensive National HIV/AIDS Strategy Federal Implementation Plan that provides an important road map for reducing new HIV infections by 90% by 2030.
IDSA and HIVMA are immensely grateful for Dr. Anthony Fauci’s contributions to the identification, treatment and containment of infectious diseases through his 38 years of leadership of the National Institute of Allergy and Infectious Diseases.
IDSA and HIVMA say that while barriers to ending the HIV epidemic are significant, the goal could be within reach with broad-based policy reforms at the federal, state and local levels.
IDSA applauds new legislation introduced by Rep. Sean Patrick Maloney (D-NY) to ensure monkeypox testing is available at no cost to the public.
IDSA and HIVMA support the Biden Administration’s decision to declare the monkeypox outbreak a public health emergency.
As monkeypox cases top more than 5,800 across 48 states, there is no time to waste.
Today’s U.S. Department of Health and Human Services announcement that nearly 800,000 additional doses of the monkeypox vaccine are now available for distribution is a welcome development, but much more is urgently needed.
IDSA and HIVMA appreciate the CDC’s swift action in responding to health care provider concerns regarding the significant procedural barriers required to obtain tecovirimat, or TPOXX, through the Expanded Access for Investigational New Drug program.
HIVMA is encouraged that funding for key HIV programs has increased in the U.S. House of Representatives Appropriations Committee’s funding bill for Labor, Health and Human Services programs for fiscal year 2023.